PUBBLICAZIONI SCIENTIFICHE

I risultati delle ricerche finanziate dalla Associazione in questi anni sono stati presentati in numerosi convegni e congressi nazionali ed internazionali e pubblicati su importanti riviste scientifiche.
  • Rivista:
  • MDPI

133 – Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers

  • AUTORI: Angela Toss, Elena Tenedini, Claudia Piombino, Marta Venturelli, Isabella Marchi, Elisa Gasparini, Elena Barbieri, Elisabetta Razzaboni, Federica Domati, Federica Caggia, Giovanni Grandi, Francesca Combi, Giovanni Tazzioli, Massimo Dominici
Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
  • Rivista:
  • MDPI

132 – The Role of Exosomes in Breast Cancer Diagnosis

  • AUTORI: Claudia Piombino, Ilenia Mastrolia, Claudia Omarini, Olivia Candini, Massimo Dominici, Federico Piacentini and Angela Toss
Abstract: The importance of molecular re-characterization of metastatic disease with the purpose of monitoring tumor evolution has been acknowledged in numerous clinical guidelines for
  • Rivista:
  • MDPI

131 – The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study

  • AUTORI: Angela Toss, Claudia Piombino, Elena Tenedini, Alessandra Bologna, Elisa Gasparini, Vittoria Tarantino, Maria Elisabetta Filieri, Luca Cottafavi, Filippo Giovanardi, Stefano Madrigali, Monica Civallero, Luigi Marcheselli
Abstract: Previous research involving epithelial ovarian cancer patients showed that, compared to germline BRCA (gBRCA) mutations, somatic BRCA (sBRCA) mutations present a similar positive
  • Rivista:
  • Original Article

130 – Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

  • AUTORI: Laura Cortesi, Federica Domati, Annalisa Guida, Isabella Marchi, Angela Toss, Elena Barbieri, Luigi Marcheselli, Marta Venturelli, Simonetta Piana, Claudia Cirilli , Massimo Federico
Abstract: The homologous recombination repair (HRR) pathway repairs double-strand DNA breaks, mostly by BRCA1 and BRCA2, although other proteins such as ATM, CHEK2, and
  • Rivista:
  • Original Article

129 – BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees

  • AUTORI: Laura Cortesi, Federica Domati, Annalisa Guida, Isabella Marchi, Angela Toss, Elena Barbieri, Luigi Marcheselli, Marta Venturelli, Simonetta Piana, Claudia Cirilli , Massimo Federico
Objective: As prostate cancer (PrC) shows a BRCA mutation rate as high as 30%, it becomes crucial to find the optimal selection criteria for
  • Rivista:
  • Academic Editor: Muhammad Shahid

128 – Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA

  • AUTORI: Claudia Piombino, Laura Cortesi, Matteo Lambertini, Kevin Punie, Giovanni Grandi, and Angela Toss
BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndromes are among the best-known and most extensively studied hereditary cancer syndromes. Nevertheless, many patients who
  • Rivista:
  • ESMO Open 6:2, 2021

127 – Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era

  • AUTORI: A. Toss 1,2* , C. Isca 1 , M. Venturelli 1 , C. Nasso 1 , G. Ficarra 3 , V. Bellelli 4 , C. Armocida 4 , E. Barbieri 1 , L. Cortesi 1 , L. Moscetti 1 , F. Piacentini 1,5 , C. Omarini 1 , A. Andreotti 6 , A. Gambini 6 , R. Battista 7 , M. Dominici 1,5 & G.
Introduction: The present analysis aims to evaluate the consequences of a 2-month interruption of mammographic screening on breast cancer (BC) stage at diagnosis and
  • Rivista:
  • British Journal of Haematology 192:6-1011:1014, 2021

126 – Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

  • AUTORI: Fulvio Massaro, Yana Stepanishyna, Martina Manni, Stefano Luminari, Sara Galimberti, Luigi Marcheselli, Carlo Visco, Cristina Tecchio, Caterina Stelitano, Francesco Angrilli, Mario Petrini, Francesco Merli and Massimo Federico
Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus HyperCVAD
  • Rivista:
  • Cancers 12:5-1252, 2020

124 – BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy

  • AUTORI: Angela Toss, Eleonora Molinaro, Marta Venturelli , Federica Domati, Luigi Marcheselli , Simonetta Piana , Elena Barbieri , Giovanni Grandi , Claudia Piombino , Isabella Marchi , Elena Tenedini , Enrico Tagliafico , Giovanni Tazzioli and Laura Cortesi
NCCN Guidelines recommend BRCA genetic testing in individuals with a probability >5% of being a carrier. Nonetheless, the cost-effectiveness of testing individuals with no
  • Rivista:
  • Lancet Haematology 7:4-e284:e294, 2020

122 – Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project

  • AUTORI: Christopher P Fox, Monica Civallero, Young-Hyeh Ko, Martina Manni, Tetiana Skrypets, Stefano Pileri, Seok Jin Kim, Maria Elena Cabrera, Andrei R Shustov, Carlos S Chiattone, Steven M Horwitz, Ivan Dlouhy, Michele Spina, Felicitas Hitz, Silvia Montoto, Arn
Background Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come
  • Rivista:
  • International Journal of Molecular Sciences 19:8-2337, 2018

121 – The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease

  • AUTORI: Maria Cosenza and Samantha Pozzi
Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has
  • Rivista:
  • Journal of Clinical Oncology (ISSN 0732-183X), 36:7-689.696, 2018

120 – Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma

  • AUTORI: Luminari S., Ferrari A., Manni M., Dondi A., Chiarenza A., Merli F., Rusconi C., Tarantino V., Tucci A., Vitolo U., Kovalchuk S., Angelucci E., Pulsoni A., Arcaini L., Angrilli F., Gaidano G., Stelitano C., Bertoldero G., Cascavilla N., Salvi F., Ferreri
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab
  • Rivista:
  • Frontiers in Oncology 8-254, 29

118 – LonP1 differently modulates mitochondrial function and bioenergetics of primary versus metastatic colon cancer cells

  • AUTORI: Gibellini L., Losi L., De Biasi S., Nasi M., Lo Tartaro D et al
Mitochondrial Lon protease (LonP1) is a multi-function enzyme that regulates mitochondrial functions in several human malignancies, including colorectal cancer (CRC). The mechanism(s) by which
  • Rivista:
  • British Journal of Haematology 181:6-760:769, 2019

116 – Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), AS new prognostic model developed by the International T-cell Project Network

  • AUTORI: Federico M., Bellei M., Marcheselli L., Schwartz M., Manni M., Tarantino V. et al
Different models to investigate the prognosis of peripheral T cell lymphoma not otherwise specified (PTCL-NOS) have been developed by means of retrospective analyses. Here
  • Rivista:
  • Oncotarget 8:61-103797:103814, 2017

114 – Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases

  • AUTORI: Civallero Monica, Cosenza Maria, Pozzi Samantha, Sacchi Stefano
JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies. Ruxolitinib is a pyrrolo[2.3-d]pyrimidine
  • Rivista:
  • Apoptosis, 22:6-827:840, 2017

112 – Ricolinostat a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine

  • AUTORI: Cosenza M., Civallero M., Marcheselli L., Sacchi S., Pozzi S.
Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biological process including cell cycle and apoptosis. We investigated
  • Rivista:
  • Hematological Oncology 35:4-630:636, 2016

110 – Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study

  • AUTORI: Monica Bellei, Elena Sabattini, Emanuela Anna Pesce et al.
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different
  • Rivista:
  • BioMed Research International, Epub 2015, August

107 – Activity of BKM120 and BEZ235 against lymphoma cells

  • AUTORI: Civallero M , Cosenza M , Pozzi S , Bari A , Ferri P , Sacchi S
Non-Hodgkin lymphomas encompass a heterogeneous group of cancers, with 85–90% arising from B lymphocytes and the remainder deriving from T lymphocytes or NK lymphocytes.
  • Rivista:
  • Mayo Clin Proc. 2015 Jun;90(6):756-64

106 – Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients

  • AUTORI: Tadmor T , Bari A , Marcheselli L , Sacchi S et al.
OBJECTIVE: To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL).
  • Rivista:
  • Annals of Epidemiology, March, 2015

104 – Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry

  • AUTORI: El Mistiri M. , Salati M. , Marcheselli L. et al.
Purpose: Despite the increasing burden of cancer occurred over recent years in the African continent, epidemiologic data from Northern Africa area have been so
  • Rivista:
  • Int. J. Cancer, 2015, Feb, 26

103 – Twenty-years experience with de novo metastatic breast cancer

  • AUTORI: Cortesi L. , Toss A. , Cirilli C. , Marcheselli L. , Braghiroli B. , Sebastiani F. et al.
Although new treatments have been widely studied to improve the survival of patients with metastatic breast cancer (BC), prognosis continues to be poor with
  • Rivista:
  • Hematol Oncol. 2014 Nov 13

102 – The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines

  • AUTORI: Cosenza M , Civallero M , Pozzi S , Marcheselli L , Bari A , Sacchi S
We analyzed the combination of a proteasome inhibitor (bortezomib) with enzastaurin (PKC/AKT-inhibitor) or lenalidomide (immunomodulatory agent) for the inhibition of proliferation and induction of
  • Rivista:
  • Br J Haematol. 2014 Jun;165(6):892

101 – Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma-response to Murphy et al

  • AUTORI: Pozzi S , Bari A , Sacchi S
The study by Murphy et al supports the observation made by several groups regarding the benefit of the novel agents in both young and
  • Rivista:
  • Expert Opin Investig Drugs. 2014 May;23(5):711-8

100 – The Potential Of Pralatrexate As A Treatment Of Peripheral T-Cell Lymphoma

  • AUTORI: Dondi A , Bari A , Pozzi S , Ferri P , Sacchi S
Introduction: Peripheral T-cell lymphomas (PTCLs) are a group of rare malignancies originating from clonal proliferation of mature, post-thymic T cells that represent 10 —
  • Rivista:
  • J Clin Oncol. 2014 Apr 20;32(12):1188-94

99 – Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial

  • AUTORI: Raemaekers JM , André MP , Federico M , Girinsky T et al.
Purpose Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET)
  • Rivista:
  • Hematol Oncol. 2015 Sep;33(3):147-51

98 – Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry

  • AUTORI: Biasoli I , Cesaretti M , Bellei M , Maiorana A et al.
We conducted a population-based study to establish the outcome of T-cell lymphoma (TCL) patients failing systemic first-line therapy. All TCL patients failing first-line systemic
  • Rivista:
  • Annals of Oncology (ISSN 0923-7534) 25-442:447, 2014

97 – The prognostic role of post-induction FDG-PET in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

  • AUTORI: Luminari S., Biasoli I., Versari A., Rattotti S., Bottelli C., Rusconi C., Merli F., Spina M., Ferreri A.J.M., Zinzani P.L., Gallamini A., Franceschetto A., Boccomini C., Franceschetti S., Salvi F., Raimondo F.D., Carella A.M., Quaresima M., Balzarotti M.
Background: [ 18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In
  • Rivista:
  • Haematologica. 2014 Jan;99(1):125-30

96 – Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

  • AUTORI: Tadmor T , Bari A , Sacchi S , Marcheselli L et al.
In this study we assessed the prognostic significance of absolute monocyte count and elected the best cut-off value at diagnosis, in a large cohort
  • Rivista:
  • Annals of Oncology (ISSN 0923-7534) 25-57:63, 2014

95 – A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women

  • AUTORI: Cortesi L., Razzaboni E., Toss A., De Matteis E., Marchi I., Medici V., Tazzioli G., Andreotti A., De Santis G., Pignatti M., Federico M.
Background: Risk-reducing mastectomy (RRM) decreases breast cancer (BC) risk in BRCA1/2 mutation carriers by up to 95%, but the Italian attitude towards this procedure
  • Rivista:
  • Blood. 2013 Nov 28;122(23):3759-66

93 – Persistence Of Minimal Residual Disease In Bone Marrow Predicts Outcome In Follicular Lymphomas Treated With A Rituximab-Intensive Program

  • AUTORI: Ladetto M , Lobetti-Bodoni C , Mantoan B , Ceccarelli M , Boccomini C , Bari A et al.
We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role
  • Rivista:
  • Br J Haematol. 2013 Oct;163(1):40-6

92 – Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis

  • AUTORI: Pozzi S , Marcheselli L , Bari A et al.
Novel treatments for multiple myeloma (MM) have shown promising results in clinical trials, but the advantage in unselected patients is still unclear. In order
  • Rivista:
  • J Clin Oncol. 2013 Sep 20;31(27):3351-9

91 – Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi

  • AUTORI: Vitolo U , Ladetto M , Boccomini C , Baldini L , De Angelis F , Bari A et al.
Purpose To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by
  • Rivista:
  • Leuk Res. 2013 Jun;37(6):619-23

90 – Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas

  • AUTORI: Bari A , Tadmor T , Sacchi S , Marcheselli L et al.
In this retrospective study we evaluated the prognostic impact of peripheral blood monocytosis in patients with T-cell non Hodgkin lymphomas with “aggressive-typically nodal presentation”.
  • Rivista:
  • Eur J Haematol. 2013 Apr;90(4):345-8

89 – Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

  • AUTORI: Voso MT , Breccia M , Lunghi M , Poloni A , Niscola P , Bari A et al.
In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important
  • Rivista:
  • International Journal of Molecolar Sciences (ISNN 1661-6596) 14:4-8271:8290, 2013

88 – Ovaria cancer: can proteomics give new insights for therapy and diagnosis?

  • AUTORI: Toss A., De Matteis E., Rossi E., Della Casa L., Iannone A., Federico M., Cortesi L.,
The study of the ovarian proteomic profile represents a new frontier in ovarian cancer research, since this approach is able to enlighten the wide
  • Rivista:
  • Annals of Oncology (ISSN 0923-7534) 24:8-2108-2112, 2013

87 – The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from FOLL05 randomized trial of the Fondazione Italiana Linfomi

  • AUTORI: Luminari S., Biasoli I., Arcaini L., Versari A., Rusconi C., Merli F., Spina M., Ferreri A.J.M., Zinzani P.L., Gallamini A., Mastronardi S., Boccomini C., Gaidano G., D’Arco A.M., Di Raimondo F., Carella A.M., Santoro A., Musto P., Federico M.:
  • Rivista:
  • J Clin Oncol. 2013 Jan 10;31(2):240-6

86 – Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project

  • AUTORI: Federico M , Rudiger T , Bellei M et al.
Purpose The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) – cell lymphomas. Patients
  • Rivista:
  • Leuk Lymphoma. 2012 Sep 28

85 – Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

  • AUTORI: Carella AM , de Souza CA , Luminari S , Marcheselli L , Chiappella A , Federico M et al.
  • Rivista:
  • Int J Cancer. 2012 Aug 23

84 – Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years

  • AUTORI: Cortesi L , Marcheselli L , Guarneri V , Cirilli C , Braghiroli B , Federico M et al.
Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for sensitive prognostic factors, able to help clinicians offer appropriate therapy,
  • Rivista:
  • Hematol Oncol. 2013 Jun;31(2):72-8

83 – Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions

  • AUTORI: Falorio S , Biasoli I , Luminari S , Quintana G , Musso M , Federico M et al.
  • Rivista:
  • Tumori (ISSN 0300-8916), 98:6-743:750, 2012

82 – Outcome evaluation in pre- trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women

  • AUTORI: Cortesi L., De Matteis E., Cirilli C., Marcheselli L., Proietto M., Federico M.

RICERCA SUL CANCRO

PUBBLICAZIONI SCIENTIFICHE

Tutti i nostri articoli pubblicati sulle riviste scientifiche
VAI

PROGETTI DI RICERCA

I progetti di ricerca che abbiamo sostenuto
VAI

BORSE DI STUDIO E STAGE ALL'ESTERO

Borse di studio e stage all'estero per ricercatori finanziati dall'Associazione
VAI

PREMI DI STUDIO

Premi di studio per la ricerca contro i tumori
VAI

PREMIO "PIER CAMILLO BECCARIA"

Conferito ogni anno ad un illustre studioso che si è distinto nella lotta contro i tumori
VAI

ASSOCIAZIONE ANGELA SERRA PER LA RICERCA SUL CANCRO ODV – C.F. 94012300367 – Email: serra@unimore.it
Policy Policy – Cookie Policy